Retatrutide
Three receptors. One molecule. A new conversation with metabolism.
Includes syringes & alcohol pads
HPLC-verified ≥99% purity · Certificate of Analysis
The triple agonist at the edge of metabolic research.
Retatrutide represents the current frontier of metabolic peptide research — a single molecule engineered to activate three receptors: GLP-1, GIP, and glucagon. Where its predecessors influenced appetite and insulin, retatrutide adds a glucagon dimension that modulates energy expenditure itself.
It is investigational. It is potent. It demands a slow, thoughtful titration and an informed user. For those studying the outer edge of metabolic regulation, it is the compound the field is watching.
Appetite Regulation
GLP-1 activation supports satiety signaling and glucose-dependent insulin release.
Energy Balance
The glucagon component influences metabolic rate and energy expenditure.
Body Composition
Researched for effects on fat mass and metabolic flexibility.
Glycemic Response
GIP contribution supports insulin sensitivity and post-meal glucose handling.
Reconstitution & Administration
Reconstitute with bacteriostatic water and store refrigerated. Begin at 0.5–1mg weekly and titrate slowly to manage GI tolerability.
This information is for research context. Any decisions about personal use — including dosing, timing, and cycle length — should involve a licensed medical provider familiar with your individual health.
The Timeline
Retatrutide is more potent per milligram than tirzepatide, so titration is deliberately slower. Protocols typically begin at 0.5–1mg weekly and climb by roughly 1–2mg every 4 weeks as tolerated. Most users report effects on appetite within the first 2–4 weeks; body composition changes unfold over months.
Often paired with:
Questions, answered.
"The edge of the research is quiet, careful work. This is where it lives."
Tirzepatide
The dual-agonist that redefined metabolic regulation.
NAD+
The current beneath every cellular conversation.
MOTS-C
The signal your mitochondria send to the rest of you.
For research use only. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.